ImmunityBio, Inc. (NASDAQ: IBRX) is a commercial-stage biotechnology company developing cell and immunotherapy products designed to strengthen patients' natural immune systems to combat cancer and infectious diseases. The company's mission is to reprogram patients' immune systems by amplifying both branches of immunity to attack cancerous or infected cells while building long-term immunological memory. ImmunityBio develops next-generation therapies and vaccines that harness and amplify the immune system to defeat cancers and infectious diseases. The company's vision is to transform patients' lives through cutting-edge biotechnology that treats the host rather than just the disease.
Beta · Sourced from candidate reports
Be the first to share your experience with ImmunityBio, Inc..
Your reply helps other candidates know what to expect.
